Leucine and Glutamic Acid as a Biomarker of Sarcopenic Risk in Japanese People with Type 2 Diabetes

Abstract

This study aimed to identify the serum metabolites associated with sarcopenic risk in Japanese patients with type 2 diabetes, determine the effect of dietary protein intake on the serum metabolic profile, and examine its association with sarcopenia. Ninety-nine Japanese patients with type 2 diabetes were included, and sarcopenic risk was defined as low muscle mass or strength. Seventeen serum metabolites were quantified after gas chromatography–mass spectrometry analysis. The relationship between dietary protein intake and the metabolites concerning sarcopenia was analyzed, and the factors affecting sarcopenic risk were clarified. Twenty-seven patients were classified as being at risk of sarcopenia, the same as the general risk, which was associated with older age, a longer duration of the disease, and a lower body mass index. Low levels of leucine and glutamic acid were significantly associated with low muscle strength (p = 0.002 and p < 0.001, respectively), and leucine was also associated with muscle mass (p = 0.001). Lower levels of glutamic acid had higher odds of sarcopenic risk after being adjusted for age and HbA1c (adjusted OR 4.27, 95% CI 1.07–17.11, p = 0.041), but not for leucine. Leucine and glutamic acid can serve as useful biomarkers for sarcopenia, highlighting potential targets for its prevention.

Serum dysregulation of serine and glycine metabolism as predictive biomarker for cognitive decline in frail elderly subjects

“…Concurrently, our data suggest a correlation between serum L-glutamate concentration and SMI. This is in line with previous investigations showing that glutamate is crucial in maintaining the homeostasis of energy metabolism in skeletal muscle [ 93 ]. Surprisingly, this relationship was observed in the non-frail but not in the frail group, suggesting that different biological pathways may modulate the maintenance of skeletal muscle mass across healthy and frail aging.…”

d-Pinitol Improves Diabetic Sarcopenia by Regulation of the Gut Microbiome, Metabolome, and Proteome in STZ-Induced SAMP8 Mice

“…GTRAP3-18 regulates glutamate transport as a negative regulator of EAAT3 function . Glutamate is not only crucial for energy metabolism, amino acid transport, protein biosynthesis, and neurotransmitter transmission but also has been identified as a biomarker and potential therapeutic target for sarcopenia in type 2 diabetes patients . Furthermore, our results found that DP increased the expression of Trim54 protein in the gastrocnemius of diabetic mice.…”

Personalized Nutritional Strategies to Reduce Knee Osteoarthritis Severity and Ameliorate Sarcopenic Obesity Indices: A Practical Guide in an Orthopedic Setting

“…Certain early studies found that the ratio of serum branched-chain amino acids to histidine may have potential clinical use as a KOA biomarker [ 77 ]; very recently, certain studies revealed that the serum levels of leucine and glutamic acid are potential biomarkers and are associated with a higher sarcopenic risk in individuals with type 2 diabetes [ 78 ].…”